Abbott Reports First-Quarter 2025 Results and Reaffirms Full-Year Guidance

Abbott Labs (ABT) PT Raised to $140 at Evercore ISI

Evercore ISI analyst Vijay Kumar raised the price target on Abbott Labs (NYSE: ABT) to $140.00 (from $138.00) while maintaining a Outperform rating.

The analyst comments "Thesis Update: In an environment where uncertainty is the dominating theme, ability to protect bottom-line should be appreciated.... More

Stifel Reiterates Buy Rating on Abbott Labs (ABT)

Stifel analyst Rick Wise reiterated a Buy rating and $135.00 price target on Abbott Labs (NYSE: ABT).

The analyst comments "From our perspective, Abbott's first quarter report contained few surprises, both to the upside or the downside. First quarter 2025 numbers came in largely in-line with our own projections and Consensus estimates. Reported sales at $10.36B (+6.9% y/y) were in-line with our $10.35B... More

BTIG Reiterates Buy Rating on Abbott Labs (ABT)

BTIG analyst Marie Thibault reiterated a Buy rating and $140.00 price target on Abbott Labs (NYSE: ABT).

The analyst comments "With adj. EPS two cents above expectations despite a minor sales miss, we think this was a solid quarter from Abbott. We breathe a sigh of relief to see ABT reaffirm its 2025 guide for sales, adj. operating margin, and adj. EPS. We think this matters most to investors. The company reported Q1 total revenue $10.358B (+6.9 y/y org. and +4.0% y/y rep.) that was ~$50M below consensus of $10.407B. Results were helped... More

Abbott (ABT) Tops Q1 EPS by 2c, Offers Guidance

Abbott (NYSE: ABT) reported Q1 EPS of $1.09, $0.02 better than the analyst estimate of $1.07. Revenue for the quarter came in at $10.36 billion versus the consensus estimate of $10.4 billion.

GUIDANCE:

Abbott sees Q2 2025 EPS of $1.23-$1.27, versus the consensus of $1.25.

Abbott... More